Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETX-929 in KRAS-Altered Advanced Solid Tumors
NCT07912593Phase 2Recruiting
- Sponsor
- ENSEM Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ETX-929 in colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial adenocarcinoma, Malignant Ovarian Tumor, sponsored by ENSEM Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
ETX-929
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)endometrial adenocarcinomaMalignant Ovarian Tumor
Beyond the preview
Go deeper on NCT07912593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07912593.